Treatment of myelodysplastic syndrome: Questions raised by the azacitidine experience

Journal of Clinical Oncology

Volumn 20, Issue 10, 2002, Pages 2415-2416

  Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CLOFARABINE; HOMOHARRINGTONINE; THROMBOPOIETIN; TIPIFARNIB; UNCLASSIFIED DRUG;

CANCER RESEARCH; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG APPROVAL; DRUG TARGETING; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MYELODYSPLASTIC SYNDROME; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE;

EID: 0037093240     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.20.10.2415     Document Type: Editorial

References (18)

1. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B
2. Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders
3. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase III intergroup study
4. Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS)
5. Granulocyte-macrophage colony-stimulating factor (GM-CSF) for myelodysplastic syndrome (MDS): Results of a multi-center randomized controlled trial
6. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes
7. Azacitidine in myelodysplastic syndromes: CALGB studies 8421 and 8921
8. Report of an international working group to standardize response criteria for myelodysplastic syndromes
9. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
10. Development of target-based antineoplastic agents
11. Ethics and practice: Alternative designs for phase III randomized clinical trials
12. The use of response-adaptive designs in clinical trials
13. Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications
14. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adult with refractory and relapsed acute leukemias: A phase I clinical-laboratory correlative trial
15. Phase I: Study of a farnesyl transferase inhibitor, R115777, in patients with myelodysplastic syndrome
16. Phase I and pharmacology study of clofarabine (2-CL-2′-F-deoxy-9-D-arabino-furanosyladenine) in solid and hematologic cancers
17. Homoharringtonine: History, current research, and future direction
18. Homoharringtonine inpatients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia